Science topic

Optimization - Science topic

Explore the latest questions and answers in Optimization, and find Optimization experts.
Questions related to Optimization
  • asked a question related to Optimization
Question
3 answers
I am experiencing challenges culturing Human Umbilical Vein Endothelial Cells (HUVEC) and seeking advice for optimization.
Observations:
  • Slow growth rate: My HUVEC cells exhibit a slow growth rate, reaching only around 5 million cells in an 80% confluent T75 flask.
  • Altered cell morphology: I have observed changes in cell shape between passages 5 and 18, as evidenced by the attached images for both passages.
Question:
  1. Passage number determination: Does the passage number start counting after thawing HUVECs from liquid nitrogen or upon initial plating after isolation?
  2. Optimization strategies: Based on the observations described above, I would appreciate any suggestions or recommendations for optimizing HUVEC cell culture, particularly regarding: Improving growth rate and cell yield?
Relevant answer
Answer
Hello Rahman! HUVECs are primary cells. They have a limitation proliferation. You cannot subculture in a long time (as yours is passage 18). You should use the same passage numbers (in around 3 subculture passages) of HUVEC cells for the whole of your project to maintain similar morphology and properties. Passages 5 and 18 are quite far together. Their characteristics might be changed.
  • asked a question related to Optimization
Question
3 answers
I would like to inquire about the theory titled ‘Geometric Mean Optimizer for Solving a Problem of a Real-Life Embedded System Application.’ Any information, no matter how small, would be greatly appreciated.
Relevant answer
Answer
For a project based on "Geometric Mean Optimizer for Solving a Problem of a Real-Life Embedded System Application," here are some of the most promising topics to explore as a basis for your master’s thesis:
  1. Battery Life Optimization in Wearable Devices:Develop an optimization framework using the geometric mean to balance power usage and performance in wearable devices. This could involve optimizing sensor sampling rates and data processing frequencies to extend battery life without compromising functionality.
  2. Real-Time Task Scheduling in IoT Networks:Implement a geometric mean optimizer to handle real-time task scheduling for IoT devices, focusing on balancing latency and throughput. This is particularly relevant for applications like smart homes, agriculture, or healthcare, where multiple devices need coordinated, efficient operation.
  3. Optimization of Signal Processing in Low-Power Embedded Systems:Many embedded systems process sensor signals, such as for noise reduction or frequency filtering. A geometric mean-based approach could optimize filter parameters to achieve a balance between processing speed and signal accuracy, especially in audio or biomedical signal processing.
  4. Energy-Efficient Edge Computing for AI:Use a geometric mean optimizer to adjust parameters in AI models running on embedded devices, balancing memory, processing power, and inference accuracy. This could apply to image or speech recognition on edge devices, where battery life is crucial.
  5. Optimizing Wireless Communication Protocols for Sensor Networks:Apply the geometric mean optimizer to improve energy efficiency in wireless sensor networks by optimizing transmission power, frequency, and data compression. This could benefit applications in remote monitoring, environmental sensors, or industrial IoT networks.
  6. Motor Control Optimization in Embedded Robotics:Robotics applications often rely on precise motor control. A geometric mean optimizer could help achieve smoother motor performance by balancing speed, torque, and energy efficiency. This can be especially useful in applications requiring delicate movements or power-constrained environments, such as in autonomous drones or mobile robots.
  7. Resource Management in Multi-Core Embedded Processors:Optimize resource allocation across multiple cores, aiming to balance performance, power, and thermal constraints. This can help in applications like automotive systems, where multiple embedded processors need to operate harmoniously for tasks like real-time data processing and safety monitoring.
  8. Thermal Management for Embedded Systems in Harsh Environments:In applications like aerospace or industrial embedded systems, thermal stability is crucial. A geometric mean optimizer could adjust workload distribution or power settings to maintain stable temperatures, balancing energy efficiency with thermal safety.
Each of these topics provides a strong basis for exploring and demonstrating the value of a geometric mean optimizer in improving specific performance metrics in embedded systems, positioning you well for a deeper thesis project.
  • asked a question related to Optimization
Question
7 answers
I got an problem solving a MIQCP: I want to cut my feaseable region into to spaces with a quadratical constraints (half circle). For points inside my half circle there is no problem, but the area outsid is a non-convex one. I use disjunctive programming to activite only one of the constraints. Is there any way to solve such a problem with Cplex in Matlab (cplexmiqcp())? Would be very grathefull if someone have experience with such a problem and can share his knowledge with me :)
Best regards,
Jannik
Relevant answer
Answer
I have this type of error
Warning: CPLEX: Q matrix is not positive semi-definite.
Warning: Model status 13: Error no solution, Solver status 9: Error: Setup failure (see message window).
solver is CPLEX 22.1 and model type is MIQCP
  • asked a question related to Optimization
Question
1 answer
Dear Colleagues,
I hope this message finds you well. I am working on a research project involving the development of a Mixed-Integer Linear Programming (MILP) model for optimizing quality-based supply chain management, particularly focusing on managing the deterioration of perishable food items.
I have written the preliminary LINGO code for this model, but unfortunately, it is not functioning as expected. The variable values (solutions) are incorrect or not converging as anticipated, and despite my best efforts, I am unable to resolve the issue.
I am genuinely seeking help from someone with expertise in MILP modeling and supply chain optimization who can assist me in debugging and improving the code. Your contribution would be highly valuable, and in recognition of your efforts, I would be more than happy to offer co-authorship on the paper once the work is successfully completed.
If you are willing to help or guide me through the corrections, please do not hesitate to reach out. I would greatly appreciate any advice or support.
Looking forward to your response.
Best regards, Ashish Kumar
Relevant answer
Answer
确保食品的质量和新鲜度,最大化利润,最小化损失
  • asked a question related to Optimization
Question
5 answers
I made a DesignBuilder model that includes PV solar collectors using two electric load centers. After simulation, the annual PV generation was about + 3700 KWh.
Then, I identified an optimization problem with two objectives (minimize thermal discomfort and maximize PV electricity generation). The decision variables are windows ratios, wall materials, and building rotation, while any parameters related to PV solar collectors design are kept constant.
In the optimization results, the power generation values are negative. Consequently, the optimum design scenarios and the pareto front are misleading.
Relevant answer
Answer
It sounds like there might be an issue with how the PV generation data is being interpreted or calculated in the optimization process. Here are a few steps to troubleshoot:
  1. Verify Data Consistency: Ensure that the units and data inputs for PV generation and load centers are consistent throughout the model and optimization process.
  2. Check Constraints and Objectives: Review the optimization constraints and objectives to make sure they are correctly defined and that they align with the expected results for PV generation.
  3. Review Simulation Settings: Double-check the simulation settings to ensure that the PV systems and their outputs are correctly modeled, and confirm that any assumptions about PV design parameters are accurate.
  4. Inspect Optimization Algorithm: Evaluate if the optimization algorithm used might be incorrectly interpreting or processing the PV generation data. Adjust algorithm settings if necessary.
  5. Analyze Results: Look into the specific cases where power generation values are negative to identify any anomalies or errors in the results.
Addressing these aspects should help in diagnosing and fixing the issue with the optimization results.
  • asked a question related to Optimization
Question
3 answers
Relevant answer
Answer
Hort Tandem Repeat (STR) testing, often used in forensic science and genetic analysis, is a powerful tool for identifying individuals based on the number of repeating units at specific locations in their DNA. STR testing can still identify someone with a germ-line mutation by detecting changes in the repeat patterns at specific DNA loci. If a germ-line mutation alters an STR region, the individual’s STR profile may show a new allele or a different number of repeats than expected based on their relatives. This can result in mismatches in parent-child STR profiles, which might indicate a mutation. While STR testing is generally reliable, the results must be carefully interpreted.
  • asked a question related to Optimization
Question
3 answers
I am optimizing a multi-stage optimization model for disaster response relief delivery. In this regard, I want to know the realistic values of cost parameters related to the operating and setup costs of temporary relief logistics facilities.
Can anyone guide me what are the realistic ranges of these costs, and how they are related to each other, and with the capacity of temporary relief facilities?
Also, please comment on the effect of the planning horizon's length on these costs.
Relevant answer
Answer
1. Cost Parameters for Temporary Relief Logistics Facilities
A. Setup Costs:
  • Construction and Installation: These include the costs of setting up temporary facilities such as tents, mobile units, or modular buildings. Costs can vary significantly based on the type and scale of the facility. Typical Ranges: Setup costs can range from a few thousand dollars for simple tents to several million dollars for larger modular units with full amenities. Factors Influencing Costs: Location, infrastructure requirements (e.g., utilities, access roads), and the facility's scale.
B. Operating Costs:
  • Maintenance and Utilities: These cover expenses for maintaining the facility and providing utilities such as electricity, water, and sanitation.Typical Ranges: Operating costs might range from $500 to $5,000 per day, depending on facility size and complexity. Factors Influencing Costs: Duration of use, local utility rates, and facility size.
  • Staffing and Supplies: Costs related to personnel (e.g., security, administrative staff) and supplies (e.g., medical equipment, food).Typical Ranges: Staffing costs can vary widely based on the number and type of staff. Supplies costs depend on the nature of relief activities.
2. Relationship Between Costs and Facility Capacity
  • Scaling Costs: As the temporary relief facility's capacity increases, both setup and operating costs generally increase, but not necessarily in a linear fashion. Larger facilities may benefit from economies of scale, where the cost per unit decreases as the size increases. For example, a larger facility might have a higher initial setup cost, but the per-person cost of providing services may decrease.
  • Capacity Planning: To optimize costs, it's essential to match the facility’s capacity with anticipated demand. Underestimating capacity can lead to higher per-unit costs due to inefficiencies and overcrowding while overestimating can lead to higher fixed costs.
3. Effect of Planning Horizon’s Length on Costs
  • Short-Term vs. Long-Term Costs: The length of the planning horizon affects both setup and operating costs. Short-Term Planning: Short-term facilities might have higher per-day costs due to the temporary nature of the setup and possible lack of economies of scale. Long-Term Planning: Longer-term facilities might benefit from more efficient resource use and lower per-day costs, but they also incur additional costs related to long-term maintenance and staffing.
  • Cost Trade-offs: Longer planning horizons might allow for more permanent or semi-permanent solutions that reduce daily operating costs but increase upfront setup costs. Balancing these trade-offs is crucial for cost-effective planning.
4. Practical Recommendations
  • Benchmarking: Review case studies and reports from similar disaster response scenarios to understand realistic cost ranges. Organizations like the World Health Organization (WHO), the United Nations (UN), and various NGOs often publish cost data related to disaster response facilities.
  • Cost Modeling: Use cost models that account for both fixed and variable costs and incorporate scenarios for different facility sizes and durations. Tools like Excel or specialized optimization software can help develop these models.
  • Consult Experts: Engage with experts in disaster response logistics and facility management to get accurate cost estimates and insights into cost management strategies.
Summary
  • Setup Costs: Typically range from thousands to millions of dollars, depending on facility type and scale.
  • Operating Costs vary from $500 to $5,000 per day, influenced by facility size and local conditions.
  • Capacity Relationship: Larger facilities may have higher setup costs but lower per-unit operating costs.
  • Planning Horizon: Longer horizons might reduce per-day costs but increase initial setup costs. Your model should consider both short-term and long-term implications.
Understanding these cost parameters and their relationships will help you optimize your disaster response logistics model effectively.
  • asked a question related to Optimization
Question
2 answers
My name is Apurva Saoji. I am a Ph.D scholar  in Computer engineering in India. I am looking for international expert in reviewing my PhD thesis, "Competitive Optimization Techniques to Minimize Energy Consumption in Wireless Sensor Network," Kindly do the needful.
Relevant answer
Answer
Your advisor should contact some of the authors whose work you have cited in your thesis. Today, with tools like LinkedIn and Research Gate, contacting experts may not be difficult.
  • asked a question related to Optimization
Question
6 answers
I have a function of the form a+(b*r^u) + c*u where a, b, r and c are dependent variables and u is the independent variable.
I am trying to optimize on a, b, r and c by setting a least-squares objective function in COMSOL Multiphysics using the Nelder Mead solver.
I have specified appropriate bounds for the variables, tightening them after each trial when the solver fails to converge, with no solution in sight.
Any recommendations on why it would not converge?
Relevant answer
Answer
Thank's very lot.
  • asked a question related to Optimization
Question
2 answers
When working on performance-critical applications in C++, understanding where and how your program spends its time is crucial. Two powerful tools that can help with this are gperftools and Chrono. This blog post will provide an overview of how these tools can be leveraged to profile and optimize your C++ applications effectively.
Related Paper:
Article Unleashing the Potential of C++: Using Optimization Techniqu...
gperftools: In-Depth Performance Profiling
gperftools, also known as Google Performance Tools, is a suite of performance analysis tools that includes CPU and memory profilers.
Key Features:
  • CPU Profiling: Identifies which parts of your code consume the most CPU time, helping to pinpoint bottlenecks.
  • Heap Profiling: Tracks memory allocations to detect leaks and optimize usage.
  • Tcmalloc: A fast memory allocator that can improve application performance by replacing the default allocator.
Usage Steps:
  1. Installation: Easily installable on most systems using package managers.
  2. Instrumentation: Simple integration into your C++ code with minimal changes.
  3. Analysis: Generates detailed reports that highlight performance issues, which can be visualized using various tools.
gperftools is particularly useful for identifying inefficiencies in large and complex applications, allowing developers to focus their optimization efforts where they are most needed.
Chrono: High-Precision Timing
Chrono is a part of the C++11 standard library, designed for high-precision time measurement and manipulation.
Key Features:
  • High-Resolution Clocks: Provides precise time measurements down to microseconds and nanoseconds.
  • Duration Arithmetic: Simplifies operations with different time units.
  • Steady Clock: Ensures consistency in timing, unaffected by system clock changes.
Usage Steps:
  1. Integration: Easily included in your C++ projects as it is a standard library component.
  2. Measurement: Offers straightforward syntax for measuring elapsed time with high precision.
  3. Reporting: Allows developers to report timing results in various units, aiding in the fine-tuning of performance-critical code sections.
Chrono is ideal for scenarios where precise timing is essential, such as measuring the performance of specific code segments or functions.
Combining gperftools and Chrono
Using gperftools and Chrono together provides a comprehensive approach to performance optimization. While gperftools identifies where the bottlenecks and inefficiencies are, Chrono measures the exact time taken by specific code sections, allowing for targeted optimizations.
Benefits of Combined Usage:
  • Detailed Insights: gperftools offers a broad view of performance issues, and Chrono provides precise timing for critical sections.
  • Targeted Optimization: By combining profiling data with precise timing, you can focus on optimizing the most impactful areas of your code.
  • Improved Efficiency: This dual approach helps in achieving significant performance improvements, ensuring your application runs faster and more efficiently.
Conclusion
Optimizing C++ applications requires a thorough understanding of both where and how time is being spent during execution. gperftools and Chrono are invaluable tools that, when used together, provide a detailed and precise picture of your program's performance.
By integrating these tools into your development workflow, you can systematically identify and address performance bottlenecks, leading to faster, more efficient applications. Whether you're dealing with CPU-bound operations or need precise timing measurements, gperftools and Chrono offer the capabilities you need to enhance your C++ application's performance.
Note by
Kazi Redwan
Lead, Team Tech Wing
Department of Computer Science
American International University-Bangladesh (AIUB)
Related Paper:
Details:
Relevant answer
Answer
Enhancing C++ Performance with gperftools and Chrono
In the realm of C++ development, achieving optimal performance is a constant pursuit. Two powerful tools can significantly improve your code's efficiency: gperftools and Chrono. This blog post will delve into how these tools can be leveraged to streamline your C++ applications.
gperftools: A Treasure Trove of Performance Insights
gperftools, developed by Google, is a collection of open-source performance analysis tools. It provides a comprehensive suite of utilities to pinpoint bottlenecks and optimize your code. Here are some of gperftools' gems:
  • CPU Profiling: The cpuprofiler tool measures how much time your program spends executing different parts of the code. This pinpoints areas that consume excessive CPU resources and helps you prioritize optimization efforts.
  • Memory Profiling: The heapcheck tool meticulously examines your program's memory allocation and deallocation patterns. It can detect memory leaks, excessive allocations, and other memory-related issues that can cripple performance.
  • Sampling Profiler: The pprof tool is a versatile sampling profiler that gathers data about your program's execution at regular intervals. This offers insights into function call stacks and helps identify performance hotspots.
By incorporating gperftools into your development workflow, you gain valuable insights into your code's performance characteristics. You can then use this knowledge to target specific areas for optimization and make data-driven decisions to enhance your application's speed and efficiency.
Chrono: Mastering the Art of Time Measurement
Time measurement is fundamental to performance analysis. The Chrono library, part of the C++ standard library (C++11 onwards), provides a robust and versatile framework for measuring time intervals and durations. Here's how Chrono empowers you:
  • High-Resolution Clock: Chrono offers access to high-resolution clocks, allowing you to measure time intervals with exceptional precision. This is particularly beneficial for performance-critical sections of your code where precise timing is essential.
  • Time-Point and Duration: Chrono introduces the time_point and duration classes, enabling you to represent points in time and elapsed time intervals with great accuracy.
  • Convenient Utilities: Chrono includes a set of convenient utilities for working with time measurements. These utilities streamline common tasks such as calculating elapsed time, converting between time units, and formatting timestamps.
By leveraging Chrono's capabilities, you can meticulously measure the execution time of different parts of your code. This fine-grained analysis empowers you to identify performance bottlenecks and optimize your code for efficiency.
Combining Forces: A Symbiotic Relationship
gperftools and Chrono work exceptionally well together. You can use gperftools to identify performance bottlenecks in your code, and then use Chrono's high-precision time measurement to pinpoint the exact source of the issue within that code section. This symbiotic relationship empowers you to make targeted optimizations that yield significant performance improvements.
  • asked a question related to Optimization
Question
5 answers
Relevant answer
Answer
Optimizing C++ with gperftools
gperftools (Google Performance Tools) includes several tools to optimize the performance of your code:
1. CPU Profiling with gperftools
Profiling helps to identify which parts of your code take the most time.
  • Collecting a Profile:
Compile your program with profiling support:
g++ -o myprogram myprogram.cpp -lprofiler
Run the program with profiling:
CPUPROFILE=/tmp/myprogram.prof ./myprogram
Analyzing the Profile:
Use pprof for analysis:
pprof --text myprogram /tmp/myprogram.prof
For visualization, use:
pprof --pdf myprogram /tmp/myprogram.prof > output.pdf
2. Using tcmalloc to Speed Up Memory Operations
tcmalloc (Thread-Caching Malloc) improves performance by managing memory more efficiently.
Installation and Usage:
nstall gperftools:
sudo apt-get install google-perftools
Link your program with tcmalloc:
g++ -o myprogram myprogram.cpp -ltcmalloc
3. Using the Heap Profiler
The heap profiler helps identify memory leaks and understand memory usage.
Collecting Heap Information:
Run your program with heap profiling:
HEAPPROFILE=/tmp/myprogram-heap ./myprogram
Analyzing the Heap:
Use pprof for analysis:
pprof --text myprogram /tmp/myprogram-heap.0001.heap
Optimizing C++ with Chrooo
Currently, there is no known tool named Chrooo associated with C++ optimization. If you meant another tool or if there was a typo, please provide more details so I can give you accurate information.
General C++ Optimization Tips
  • Avoid Unnecessary Copying: Use references and pointers instead of copying large objects.
  • Use Efficient Containers: For example, prefer std::vector over std::list for sequential access.
  • Inline Functions: Use inline for small, frequently called functions.
  • Parallelization: Use multithreading and libraries like OpenMP or Intel TBB for parallel processing.
If you have more specific questions or need assistance with these tools, please let me know.
Best regards, Oleh Chashyn
  • asked a question related to Optimization
Question
1 answer
. How does the management of electrolyte disturbances differ in emergent versus non-emergent settings?
Relevant answer
  • asked a question related to Optimization
Question
1 answer
What factors contribute to the development of hypomagnesemia in critically ill patients, and how should it be treated?
Relevant answer
  • asked a question related to Optimization
Question
1 answer
What are the causes and clinical manifestations of hypophosphatemia, and how should it be managed in critically ill patients?
Relevant answer
  • asked a question related to Optimization
Question
1 answer
What are the diagnostic steps and treatment strategies for hyperkalemia in the ICU?
Relevant answer
  • asked a question related to Optimization
Question
1 answer
How does succinylcholine use in critically ill patients relate to the risk of acute hyperkalemia?
Relevant answer
Answer
https://www.researchgate. net/publication/380823913_Optimizing_Fluid_and_Electrolyte_Management_in_the_Intensive_Care_Unit_A_Comprehensive_Review?_sg%5B0%5D=IxlDZHVdSAO32fi2N6CoPJRvHGHCHIRHun5d9s0HImp3HmIQ5XhX0tt2fpfwR9GASb6OpBjsdiJcoae1ZINFpohQTO0gtomXLdp5nOGy.ceojn0eBdHakm_VzPHFlIgbhtbZhZ5G-tJx9bwx4w6QFoTzuXmJsGro2Qy3yaWrj1Dw1SQpi3tWSKFnaQtZWGQ&_tp=eyJjb250ZXh0Ijp7ImZpcnN0UGFnZSI6InByb2ZpbGUiLCJwYWdlIjoicHJvZmlsZSIsInByZXZpb3VzUGFnZSI6InByb2ZpbGUiLCJwb3NpdGlvbiI6InBhZ2VDb250ZW50In19
  • asked a question related to Optimization
Question
1 answer
What are some common fluid and electrolyte disturbances encountered in the intensive care unit (ICU)?
Relevant answer
  • asked a question related to Optimization
Question
1 answer
. What are the potential adverse outcomes associated with liberal fluid administration in critically ill patients?
Relevant answer
  • asked a question related to Optimization
Question
1 answer
How does hyponatremia develop in the critical care setting, and what are its clinical manifestations?
Relevant answer
  • asked a question related to Optimization
Question
1 answer
. What are the key principles in the management of hyponatremia, particularly in symptomatic patients?
Relevant answer
  • asked a question related to Optimization
Question
2 answers
Describe the treatment approach for hypokalemia and the potential complications associated with severe hypokalemia
Relevant answer
  • asked a question related to Optimization
Question
2 answers
Can you describe the process for initiating and titrating clozapine therapy in a patient with treatment-resistant schizophrenia?
Relevant answer
Answer
These should address your questions:
----------------------------------------------------------------------------
Found in the National Library of Medicine:
CNS Drugs. 2022; 36(7): 659–679.
Published online 2022 Jun 27. doi: 10.1007/s40263-022-00932-2
PMCID: PMC9243911
PMID: 35759211
A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia
C. U. Correll,1,2,3 Ofer Agid,4 Benedicto Crespo-Facorro,5 Andrea de Bartolomeis,6 Andrea Fagiolini,7 Niko Seppälä,8 and Oliver D. Howes 9
Author information Article notes Copyright and License information PMC Disclaimer
This article has been corrected. See CNS Drugs. 2022 August 17; 36(9): 1015.
Abstract
Treatment-resistant schizophrenia (TRS) will affect about one in three patients with schizophrenia. Clozapine is the only treatment approved for TRS, and patients should be treated as soon as possible to improve their chances of achieving remission. Despite its effectiveness, concern over side effects, monitoring requirements, and inexperience with prescribing often result in long delays that can expose patients to unnecessary risks and compromise their chances of achieving favorable long-term outcomes. We critically reviewed the literature on clozapine use in TRS, focusing on guidelines, systematic reviews, and algorithms to identify strategies for improving clozapine safety and tolerability. Based on this, we have provided an overview of strategies to support early initiation of clozapine in patients with TRS based on the latest evidence and our clinical experience, and have summarized the key elements in a practical, evidence-based checklist for identifying and managing patients with TRS, with the aim of increasing confidence in prescribing and monitoring clozapine therapy.
Key Points
Early and sustained treatment with clozapine represents the best available strategy for achieving and maintaining remission in patients with treatment-resistant schizophrenia.Common side effects including sialorrhea, constipation and weight gain may result in poor adherence to treatment, while the existence of rare severe adverse events and the associated monitoring burden may result in delays in starting therapy.Strategies for optimizing treatment and managing side effects are summarized and a checklist is provided.
Introduction
Schizophrenia is a serious mental illness involving positive and negative symptoms, as well as cognitive impairment [1]. It has a median incidence of 287 (uncertainty interval 246–331)/100,000 [2] and median standardized mortality ratio of 2.6 [3]. Therapies targeting postsynaptic dopamine receptors are not effective in all cases, especially regarding negative symptoms and in patients with treatment-resistant schizophrenia (TRS). TRS is defined as patients who do not respond sufficiently to sequential trials of at least two different antipsychotics administered at appropriate doses, duration, and with adequate adherence from the patient [4–7].
TRS is a major clinical challenge that can occur early in the treatment pathway or develop later in patients who respond initially to antipsychotic treatment [8–10]. Several lines of evidence indicate that it has a different neurobiology to schizophrenia that responds to dopamine D2 receptor blockers [11, 12]. It has been hypothesized that TRS could represent a neurobiologically distinct sub-type of schizophrenia [13, 14]. Some data point to a sub-type of schizophrenia associated with TRS characterized by unaltered dopamine function [15–17], and glutamate dysregulation [18–20], which would explain why these patients do not respond to dopamine D2 blockers [21]. TRS occurs in 20–50% of patients with schizophrenia [22–24], including in community settings [25]. It is associated with higher disease burden [26, 27] and poorer outcomes [28], especially involving persistent positive symptoms despite adherence with treatment [29].
Clozapine is the only drug approved for TRS by regulators in North America, Europe, and many other jurisdictions. It is a tricyclic dibenzodiazepine derivative that interacts with multiple neuroreceptors, including dopamine, serotonin and muscarinic receptors [30, 31]. Its low affinity for D2 dopamine receptors may explain its relative lack of extrapyramidal side effects [30], whilst its actions to modulate glutamate levels may contribute to its superior efficacy in TRS [32]. Clozapine is more effective than other antipsychotics for TRS [33], and it reduces rates of hospital readmission and all-cause mortality [34–36]. A systematic review and meta-analysis of long-term studies (median follow-up 5.4 years) revealed that continuous clozapine treatment was associated with a significantly lower all-cause mortality rate compared to other antipsychotics (mortality rate ratio = 0.56, 95% confidence interval (CI) = 0.36–0.85, P = 0.007) [37], which may be due to reduced suicidality [38].
________________________________________________________________________________
Found in UpToDate, Wolters Kluwer, The whole article is excellent. Find the complete article at UpToDate
Schizophrenia in adults: Guidelines for prescribing clozapine
CONTRAINDICATIONS AND PRECAUTIONS NeutropeniaDuffy-null associated neutrophil count (DANC) Cardiac disease Seizures Other conditions PHARMACOLOGYPharmacodynamics Pharmacokinetics ADMINISTRATIONPretreatment assessment Dose titration and plasma levels Maintenance dosing Re-initiation after interruption MONITORING Neutrophil countRequired bloodwork and COVID-19 CardiovascularMyocarditis QTc prolongation Metabolic Gastrointestinal ADVERSE EFFECTS
Neutropenia/agranulocytosis Myocarditis/cardiomyopathy QTc interval prolongation Pulmonary embolism Weight gain Insulin resistance and diabetes mellitus Seizures Excessive salivation Urinary incontinence Gastrointestinal hypomotility Sedation Teratogenic and neonatal risks Mortality risk Movement disorders TablesCauses of long QT syndrome AUTHORS:Oliver Freudenreich, MDJoseph McEvoy, MD
SECTION EDITOR:Stephen Marder, MD
DEPUTY EDITOR:Michael Friedman, MDContributor DisclosuresAll topics are updated as new evidence becomes available and our peer review process is complete.Literature review current through: Apr 2024.This topic last updated: May 22, 2023
CONTRAINDICATIONS AND PRECAUTIONS:
Neutropenia —Duffy-null associated neutrophil count (DANC) — Lower neutrophil thresholds were established for starting and treating clozapine in patients with confirmed DANC, a cause of neutropenia not associated with recurrent or severe infection that is most often seen in individuals of African descent and Sephardic Jews [3]. Treatment can be instituted and continued in patients with an ANC of at least 1000/microL. Collaboration with hematology is recommended to manage moderate or severe neutropenia in this patient group. (See "Approach to the adult with unexplained neutropenia", section on 'Normal variants <1500/microL'.)Cardiac disease )Seizures Other conditions —PHARMACOLOGYThe pharmacologic mechanisms underlying clozapine’s superiority for treatment-resistant schizophrenia are not known.Pharmacodynamics — Clozapine binds loosely and transiently to dopamine D2 receptors. Clozapine does not induce catalepsy or inhibit apomorphine-induced stereotypy in animal models as is seen with conventional antipsychotic medications; this may explain its reduced potential for producing movement abnormalities relative to tightly binding dopamine D2 antagonists such as haloperidol. Clozapine also binds to D1, D3, and D5 receptors, and has a high affinity for the D4 receptor, but the implications of these binding activities are unclear.Clozapine also interacts at histamine H1, acetylcholine muscarinic M1 and serotonin 5-HT2A, 5-HT2C, 5-HT6, and 5-HT7 receptors, and at alpha-1-adrenoceptors. Postural dizziness, sedation, and increased appetite may reflect actions of clozapine at alpha-1, H1, and 5-HT2c receptors, respectively. Actions at the 5-HT2A and M1 receptors may reduce movement side effects [4].Pharmacokinetics — Clozapine is well absorbed. First-pass metabolism reduces its bioavailability to 60 to 70 percent of the administered dose; food has little effect on the bioavailability of clozapine. The elimination half-life of clozapine averages approximately 14 hours under steady state conditions, but there is substantial variability across individuals [5].Clozapine is extensively metabolized by the cytochrome P450 system in the liver, and excreted in both the urine and feces. Cytochrome P450 1A2 is primarily responsible for clozapine metabolism; cytochromes 2C19, 2C9, 2D6, and 3A4 play less important roles. Agents that induce cytochrome CYP1A2, such as tobacco cigarette smoke, will increase the metabolism of clozapine. Tobacco smokers may require twice the dose of nonsmokers to achieve similar blood levels. Strong inducers of CYP3A4 (eg, phenobarbital, carbamazepine) will also reduce serum concentrations of clozapine; additive bone marrow toxicity with carbamazepine has been described [6-10]. Agents that inhibit CYP1A2 (eg, ciprofloxacin, fluvoxamine) will decrease the metabolism of clozapine and may produce clinical toxicity at usual doses [11]. Cytochrome-related problems can be avoided by monitoring clozapine plasma levels while gradually increasing clozapine from a low starting dose. (See 'Dose titration and plasma levels' below.)In addition, patients prescribed clozapine should have their medication regimen analyzed for drug interactions when initiating and adjusting therapy; this may be done by use of the drug interactions program.The major metabolite of clozapine, norclozapine (desmethylclozapine), has failed to demonstrate any therapeutic activity in clinical trials. Clozapine and norclozapine plasma levels are both reported by clinical labs, but only the clozapine level is useful for dose optimization [12].
ADMINISTRATION
Pretreatment assessment — Assessment prior to treatment with clozapine should include evaluation of the patient’s general and cardiovascular health status. Other components of an evaluation include documentation and testing of:●Complete blood count that includes an absolute neutrophil count (ANC). The minimum ANC required to initiate clozapine is described above [3]. (See 'Neutropenia' above.)●Weight and height (body mass index), waist circumference, fasting blood sugar (or HbA1c), and fasting lipids. (See 'Weight gain' below and 'Insulin resistance and diabetes mellitus' below.)●Drug levels for patients on anticonvulsant medications (need to be in the therapeutic range). (See 'Seizures' below.)●Vital signs.●Electrocardiogram.●An Abnormal Involuntary Movement Scale documenting absence or presence of abnormal motor movements (form 1).●Pregnancy test in women of childbearing age.In addition, consider obtaining measures of inflammation (eg, C-reactive protein) and cardiac muscle damage (eg, troponin levels). (See 'Cardiovascular' below.)Dose titration and plasma levelsStarting dose and titration – For patients initially starting clozapine in nonurgent situations, we prefer a slow titration. As an example, we suggest 12.5 to 25 mg once daily at bedtime for three to four days, then 25 to 50 mg once daily at bedtime for three to four days. We then increase further by 25 mg twice weekly. An initial test dose of 12.5 mg is recommended to confirm tolerability in patients who have never received clozapine.In urgent situations (active aggression/violence or self-injury/suicide) we double the titration rate above. For example, we suggest 50 mg once daily for three or four days, then 100 mg once daily for three to four days followed by increases of 50 mg twice weekly. Sleepiness is the primary clinical ceiling side effect, so as clozapine dose is increasing, we simultaneously taper off other sedating agents. We monitor for seizure risk by asking patients or their families to report myoclonic jerking movements.We adjust dosing for individuals of Asian descent as they require less clozapine to reach therapeutic blood levels.●Initial target dose – The initial target dose for healthy, young adults is 300 mg/day. Older adult patients and patients with cardiac disease may need a lower target dose and a slower titration, particularly if they experience sedation or orthostatic hypotension to avoid falls or worsening cardiac function.●Target plasma levels – Plasma levels can be checked after the initial target dose is reached or earlier (eg, after reaching 100 mg). A clozapine plasma level in the range of 250 to 350 ng/mL is a reasonable target.
Maintenance dosing — A maintenance dose of 300 to 600 mg/day is usually required for efficacy. The average final daily dose in patients with treatment-resistant psychosis is approximately 400 mg daily. Doses higher than 900 mg/day are not recommended.Due to great interindividual variability in clozapine metabolism, in rare instances, levels can reach toxic range with lower doses (eg, 100 mg/day) or fail to achieve therapeutic levels at higher doses (eg, 600 to 900 mg/day). Checking plasma levels is thus important during the titration phase; however, once a target dose is achieved, ongoing plasma level monitoring is not routinely necessary. Regular therapeutic drug monitoring can help detect unsuspected adherence problems early enough to take counter measures. (See 'Dose titration and plasma levels' above.)Once the patient is stabilized on an effective maintenance dose, all or most of the daily dose may be given at bedtime. This will aid patients in getting to sleep and avoiding daytime sedation. Adherence can be improved by taking the medication at the time of routine, consistent behaviors, such as breakfast or bedtime preparations, and by prescribing once or twice daily rather than more frequently. However, some patients require split doses to avoid bed wetting or morning grogginess.Re-initiation after interruption — If clozapine treatment is interrupted for two or more days, we start clozapine at 12.5 mg once or twice daily in order to assess tolerability and decrease the risk of severe cardiovascular effects including orthostatic hypotension, syncope, and cardiac arrest [16]. If well tolerated, however, the previous dose can be achieved more quickly compared with patients who are initially started on clozapine
.MONITORING: Neutrophil count —intervals:●Weekly during the first six months of clozapine administration●Every other week for the second six months●Every four weeks after one year, for the duration of treatment. If neutropenia develops during treatment, clozapine would either need to be monitored more frequently, stopped temporarily, or discontinued, based on the severity of neutropenia [1]:●Mild neutropenia (ANC: 1000 to 1499/microL) – Continue treatment but increase monitoring frequency to three times per week.●Moderate neutropenia (ANC: 500 to 999/microL) – Interrupt clozapine treatment, increase monitoring to daily until ANC is 1000/microL at which point clozapine can be reinstituted.●Severe neutropenia/agranulocytosis (ANC: <500/microL) – Discontinue clozapine. Rechallenge should only occur if the benefits outweigh the risks
)ADVERSE EFFECTS
Neutropenia/agranulocytosis —  )Myocarditis/cardiomyopathy —QTc interval prolongation — Pulmonary embolism — Weight gain — Insulin resistance and diabetes mellitus --Seizures-- Excessive salivation —
SUMMARY AND RECOMMENDATIONS
Indications – Primary indications for clozapine include schizophrenia or schizoaffective disorder partially or fully resistant to treatment with other antipsychotic drugs, or schizophrenia/schizoaffective accompanied by persistent suicidal or self-injurious behavior. (See 'Indications' above.)●Pretreatment assessment Prior to beginning clozapine, we do the following baseline evaluation (see 'Pretreatment assessment' above):•General and cardiovascular health status, vital signs, weight, height, body mass index•Complete blood count (absolute neutrophil count [ANC] must be ≥1500/microL to initiate clozapine)•Check for therapeutic drug levels of anticonvulsant medications•Fasting blood sugar or HbA1c, fasting lipids (non-high-density lipoprotein cholesterol if nonfasting)•Electrocardiogram (ECG)•Baseline Abnormal Involuntary Movement Scale test•Pregnancy test in women of childbearing age
Administration For patients initially starting clozapine in nonurgent situations, we prefer a slow titration. As an example, we suggest 12.5 to 25 mg once daily at bedtime for three to four days, then 25 to 50 mg once daily at bedtime for three to four days. We increase by 25 mg twice weekly. In urgent situations (active aggression/violence or self-injury/suicide) we double the titration rate above.The initial target dose for healthy, young adults is 300 mg/day. A maintenance dose of 300 to 600 mg/day is usually required for efficacy. Doses higher than 900 mg/day are not recommended. We are cautious with older adults (>65 years) and in individuals with comorbid medical or cardiac disease. Typical maintenance dose may be as low as 100 to 150 mg/day. We titrate slowly in these individuals to avoid adverse effects. We check plasma levels once target dose is reached or earlier (after 100 mg are reached). (See 'Administration' above.)●Monitoring – For all patients taking clozapine in the United States, the US Food and Drug Administration requires regular monitoring and registry reporting of neutrophil counts. Patients taking clozapine should receive routine weekly-to-monthly monitoring and maintain an ANC ≥1500/microL (≥1000/microL for individuals with Duffy-null associated neutrophil count. Lower ANC levels require more frequent monitoring, and possible interruption of clozapine and/or reevaluation of its use. Monitoring frequency is as follows (see 'Monitoring' above):•Weekly during the first six months of clozapine administration•Every other week for the second six months•Every four weeks after one year, for the duration of treatmentIf neutropenia develops during treatment, clozapine we either monitored more frequently, stopped the medication temporarily, or discontinued the medication, based on the severity of neutropenia.●Adverse effects (see 'Adverse effects' above)•Neutropenia/agranulocytosis – Clozapine-induced agranulocytosis occurs at a rate of approximately 0.8 percent. Leukopenia occurs in approximately 3 percent of cases. The peak risks for both occurred early in treatment, between 6 to 18 weeks from initiation. (See 'Neutropenia/agranulocytosis' above.)•Cardiovascular effects – Clozaril is associated with early myocarditis that can lead to the development of cardiomyopathy. Additionally, it can cause a dose dependent QTc prolongation. We obtain an ECG prior to starting clozapine; we repeat the ECG once steady state is obtained. (See 'Myocarditis/cardiomyopathy' above.)•Insulin resistance, weight gain, metabolic dysregulation – Clozapine can cause insulin resistance, metabolic dysregulation and weight gain. While most weight gain occurs during the first 6 to 12 months, some patients continue to gain weight without reaching a plateau. We monitor metabolic parameters at regular intervals. (See 'Insulin resistance and diabetes mellitus' above.)•Seizures – Clozapine is associated with a dose-dependent seizure risk at a rate higher than that seen with most other antipsychotic drugs (See 'Seizures' above.)•Other effects – Treatment with clozapine can cause constipation, sedation, sialorrhea, incontinence, pulmonary embolism. Treatment with antipsychotics including clozapine is associated with increased mortality in individuals with dementia. (See 'Adverse effects' above.)
  • asked a question related to Optimization
Question
2 answers
What strategies can be employed to address antimicrobial resistance and promote responsible antibiotic prescribing?
Relevant answer
Answer
Antimicrobial resistance (AMR) is a significant global health concern that requires a multifaceted approach to address it effectively. Here are several strategies that can be employed to tackle AMR and promote responsible antibiotic prescribing:
1. Enhance public awareness and education: Educating the public about the appropriate use of antibiotics, the consequences of AMR, and the importance of completing prescribed antibiotic courses is crucial. Public awareness campaigns can be conducted through various channels, including schools, healthcare facilities, media, and community outreach programs.
2. Strengthen surveillance and monitoring: Establish robust surveillance systems to monitor AMR patterns, antibiotic consumption, and the emergence of new resistant strains. This data can guide evidence-based policies and interventions while providing early warning signs for outbreaks or resistance hotspots.
3. Implement antibiotic stewardship programs: These programs aim to optimize antibiotic use by promoting appropriate prescribing practices. They involve guidelines, protocols, and interventions that encourage healthcare professionals to prescribe antibiotics only when necessary, select the right antibiotics, and use the correct dosage and duration.
4. Improve infection prevention and control: Emphasize the importance of infection prevention measures, such as hand hygiene, vaccination, and sanitation practices. Effective infection control measures can reduce the need for antibiotics by preventing infections in the first place.
5. Strengthen healthcare systems: Enhance healthcare infrastructure, especially in resource-limited settings, to ensure access to quality diagnostics, appropriate antibiotics, and effective surveillance. This includes training healthcare professionals in rational antibiotic use, providing access to essential medicines, and improving laboratory capacity for accurate diagnosis.
6. Foster research and development: Encourage research and development for new antibiotics, diagnostics, and alternative treatment options. Incentives can be provided to promote innovation in this field, as the development of new antimicrobial drugs has been limited in recent years.
7. Promote international collaboration: AMR is a global issue that requires international cooperation. Encourage collaboration among countries to share best practices, exchange information, and coordinate efforts to address AMR comprehensively.
8. Regulate antibiotic use in agriculture: Implement regulations and guidelines to ensure responsible use of antibiotics in agriculture and livestock farming. This includes promoting alternatives to antibiotics, restricting the use of antibiotics for growth promotion, and monitoring antibiotic residues in food products.
9. Encourage research on novel therapies: Explore and support research on alternative therapies, such as phage therapy, monoclonal antibodies, and probiotics, which may provide effective alternatives to antibiotics in certain situations.
10. Promote innovation in diagnostics: Develop and promote rapid and accurate diagnostic tools that can identify pathogens and their susceptibility to antibiotics. This can help healthcare professionals prescribe antibiotics more precisely, reducing unnecessary prescriptions.
  • asked a question related to Optimization
Question
2 answers
How can healthcare organizations measure the effectiveness of their antimicrobial stewardship efforts?
Relevant answer
Answer
Various methods, including- 1.Resistance Surveillance 2.Antibiotic Utilization Metrics
3.Clinical outcome
4.Education and Training
5.Adherence to Guidelines
6.Cost Analysis
7.Patient satisfaction
8.Antimicrobial Stewardship Program (ASP) Metrics.
  • asked a question related to Optimization
Question
3 answers
I would like to optimize my extraction using responce surface methodology but I‘m perplexed in choosing what design should I use? I just have 2 factors with 2 levels each, so I considered using CCD but I don’t understand the basic of the run test results which have some replication or about the lack of fits (is this crucial?). If I change it to no replication or minimizing lack of fits, is it ok? Or should I consider another design?
thank you very much for your kind response
Relevant answer
Answer
Lack of fit F test is used to test the hypothesis of model correctness: that is whether there is statistically significant model misspecification in not.
In RSM, the Lack of fit test is used to determine whether there is significant curvature in the experimental data: the first order model with interaction term is not able to capture adequate data variation and hence a second order model based design (CCD or Box Behnken type) is needed to fit the data coming from this particular region of the experimental space.
Details about the RSM process and statistical tests associated with it can be found in the following books:
1) Chemometrics: Experimental Design by Ed Morgan
2) Response Surface Methodology by Myers, Montogomery and Cook
  • asked a question related to Optimization
Question
2 answers
What is the role of interprofessional collaboration in optimizing outcomes with ivabradine therapy?
Relevant answer
Answer
Interprofessional collaboration plays a vital role in optimizing outcomes with ivabradine therapy by leveraging the expertise and perspectives of multiple healthcare disciplines to provide comprehensive care and support to patients. Here's how interprofessional collaboration contributes to optimizing outcomes with ivabradine therapy:
  1. Comprehensive Assessment: Different healthcare professionals, including cardiologists, internists, pharmacists, and nursing staff, contribute their expertise to conduct a comprehensive assessment of patients' clinical status, including heart function, comorbidities, medication history, and potential contraindications or risk factors for ivabradine therapy.
  2. Treatment Planning: Collaborative discussions among healthcare team members facilitate the development of individualized treatment plans tailored to each patient's needs, preferences, and treatment goals. This may include selecting the appropriate dose of ivabradine, titrating medications, and addressing potential drug interactions or contraindications.
  3. Patient Education: Pharmacists and nursing staff play a crucial role in educating patients about ivabradine therapy, including proper medication administration, dosage instructions, potential side effects, and the importance of adherence to treatment. Clear communication and patient-centered education empower patients to actively participate in their care and make informed decisions.
  4. Monitoring and Follow-Up: Regular monitoring of patients' clinical status, including heart rate, cardiac rhythm, and symptoms, is essential for assessing treatment efficacy and safety. Nursing staff and healthcare providers collaborate to ensure timely follow-up visits, monitor adverse effects, and address any concerns or issues related to ivabradine therapy.
  5. Adverse Event Management: Prompt identification and management of adverse events or complications associated with ivabradine therapy require close collaboration among healthcare team members. Pharmacists, nursing staff, and healthcare providers work together to assess patients' symptoms, adjust medication regimens as necessary, and provide supportive care to minimize discomfort and optimize treatment outcomes.
  6. Continuity of Care: Seamless transitions of care between healthcare settings, such as hospital, clinic, and home, are facilitated through interprofessional collaboration. Effective communication and coordination ensure that patients receive consistent monitoring, follow-up care, and medication management throughout their treatment journey, reducing the risk of hospital readmissions and improving patient outcomes.
Overall, interprofessional collaboration fosters a team-based approach to care delivery, promotes patient-centeredness, and enhances the effectiveness and safety of ivabradine therapy in optimizing outcomes for patients with heart failure.
  • asked a question related to Optimization
Question
1 answer
How should healthcare providers monitor patients receiving ivabradine therapy?
Relevant answer
Answer
Healthcare providers should monitor patients receiving ivabradine therapy through several means to ensure treatment efficacy and safety. Monitoring parameters include:
  1. Cardiac Rhythm: Regular assessment of cardiac rhythm through electrocardiogram (ECG) monitoring can help detect any arrhythmias or changes in heart rhythm, especially atrial fibrillation, which may occur as a side effect of ivabradine.
  2. Heart Rate: Monitoring of heart rate is essential to ensure that ivabradine is effectively reducing heart rate to the target range without causing excessive bradycardia. Patients should be instructed to monitor their resting heart rate regularly and report any significant changes or symptoms of bradycardia.
  3. Symptoms of Bradycardia: Patients should be educated about the signs and symptoms of bradycardia, such as dizziness, fatigue, fainting, or shortness of breath. Healthcare providers should inquire about these symptoms during follow-up visits and adjust ivabradine dosage or discontinue treatment if necessary.
  4. Visual Disturbances: Patients should be monitored for visual disturbances, such as phosphenes (perceived flashes of light), which may occur as a side effect of ivabradine. Patients experiencing visual disturbances should be evaluated, and treatment adjustments may be necessary.
  5. Blood Pressure: Regular monitoring of blood pressure is recommended, as ivabradine may lead to elevated blood pressure in some patients.
  6. Liver Function Tests: Periodic assessment of liver function tests may be warranted, especially in patients with underlying liver disease or risk factors for liver impairment.
  7. Adverse Effects: Healthcare providers should inquire about any adverse effects or changes in symptoms during follow-up visits and address any concerns or issues related to ivabradine therapy.
Regular monitoring and communication between healthcare providers and patients are crucial to optimize ivabradine therapy, minimize adverse effects, and ensure patient safety and treatment efficacy.
  • asked a question related to Optimization
Question
1 answer
What are the contraindications for using ivabradine?
Relevant answer
Answer
Contraindications for using ivabradine include:
  1. Decompensated Heart Failure: Ivabradine is contraindicated in patients with decompensated heart failure, which refers to a worsening of heart failure symptoms requiring immediate medical attention and often necessitating hospitalization.
  2. Hypotension: Ivabradine should not be used in patients with blood pressure less than 90/50 mmHg.
  3. Conduction Abnormalities: Patients with certain conduction abnormalities, such as sick sinus syndrome, sinoatrial block, or third-degree atrioventricular (AV) block, should not receive ivabradine unless they have a pacemaker to determine heart rate.
  4. Severe Liver Impairment: Ivabradine is contraindicated in patients with severe liver impairment (Child-Pugh Class C).
  5. Concomitant Use of CYP3A4 Inhibitors: Ivabradine should not be used concomitantly with potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) due to the potential for increased ivabradine levels and risk of bradycardia.
  6. Resting Heart Rate Less Than 60 bpm: Ivabradine is contraindicated in patients with a resting heart rate less than 60 beats per minute before therapy initiation.
It's important for healthcare providers to assess patients for these contraindications before initiating ivabradine therapy to ensure patient safety and optimize treatment outcomes.
  • asked a question related to Optimization
Question
2 answers
How does ivabradine affect heart rate without affecting myocardial contractility?
Relevant answer
Answer
Ivabradine affects heart rate primarily by selectively inhibiting the If (funny current) channels in the sinoatrial node of the heart. These channels play a crucial role in regulating the heart's pacemaker activity by allowing the influx of sodium and potassium ions during the diastolic phase, which contributes to the spontaneous depolarization of cardiac pacemaker cells.
By blocking the If channels, ivabradine slows down the rate at which these pacemaker cells depolarize, effectively prolonging the duration of the diastolic phase of the cardiac cycle. This action leads to a reduction in heart rate without directly affecting myocardial contractility or the force of cardiac contraction.
In contrast to beta-blockers, which exert their effects on heart rate and contractility by blocking beta-adrenergic receptors, ivabradine specifically targets the If channels in the sinoatrial node, making it a selective and direct modulator of heart rate. This mechanism of action allows ivabradine to lower heart rate without compromising cardiac function, making it particularly useful in conditions such as heart failure and angina where controlling heart rate is beneficial.
  • asked a question related to Optimization
Question
1 answer
What are the common adverse effects associated with ivabradine?
Relevant answer
Answer
Common adverse effects associated with ivabradine therapy include:
  1. Bradycardia: Since ivabradine reduces heart rate, bradycardia (slow heart rate) is a common adverse effect. Patients may experience symptoms such as dizziness, fatigue, or fainting.
  2. Atrial Fibrillation: Ivabradine has been associated with an increased risk of atrial fibrillation, a type of irregular heartbeat. Patients may experience palpitations, shortness of breath, or chest discomfort.
  3. Visual Disturbances (Phosphenes): Some patients may experience visual disturbances, such as seeing flashes of light or shimmering lights, known as phosphenes. These effects are usually transient and occur due to ivabradine's inhibition of the If channels in the retina.
  4. Hypertension: Ivabradine may lead to elevated blood pressure in some patients.
  5. Other Less Common Adverse Effects: Other less common adverse effects of ivabradine include headache, dizziness, nausea, diarrhea, and fatigue.
It's essential for healthcare providers to monitor patients regularly for these adverse effects during ivabradine therapy and adjust treatment as necessary to minimize discomfort and optimize patient safety.
  • asked a question related to Optimization
Question
1 answer
What is the mechanism of action of ivabradine?
Relevant answer
Answer
The mechanism of action of ivabradine involves its selective inhibition of the If (funny current) channels in the sinoatrial node of the heart. These channels play a crucial role in regulating the heart's pacemaker activity by allowing the influx of sodium and potassium ions during the diastolic phase, which contributes to the spontaneous depolarization of cardiac pacemaker cells. By blocking the If channels, ivabradine slows down the heart rate without affecting myocardial contractility, resulting in a reduction in heart rate without negative inotropic effects. This mechanism makes ivabradine particularly useful in managing conditions such as heart failure and angina, where controlling heart rate is beneficial.
  • asked a question related to Optimization
Question
6 answers
The structure of hydroxyurea has been mentioned in different papers as a and b (attached figure). However, when I try to optimize the structure without restriction (at different theoretical levels), the resulting output is c. why does it happen?
Relevant answer
Answer
Aren't the same structures, but at 3 different orientations?
To me these look the same when mentally rotating them.
Rotation operations reach each other, right?
Maybe you may mean when OH is trans to C=O, not cis as in the 3 structures in the image.
  • asked a question related to Optimization
Question
2 answers
What are some emerging therapies or neuroprotective agents being investigated for the management of TBI?
Relevant answer
Answer
Several emerging therapies and neuroprotective agents are being investigated for the management of traumatic brain injury (TBI). While many of these interventions are still in preclinical or early clinical stages of development, they hold promise for improving outcomes and reducing long-term disability in TBI patients. Here are some examples:
  1. Neurotrophic Factors: Neurotrophic factors such as brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and glial cell line-derived neurotrophic factor (GDNF) have neuroprotective and neuroregenerative properties that may promote neuronal survival, axonal growth, and synaptic plasticity following TBI. These factors are being studied as potential therapeutic agents to enhance recovery and functional outcomes in TBI patients.
  2. Anti-inflammatory Agents: Inflammation plays a significant role in the pathophysiology of TBI, contributing to secondary brain injury and neurodegeneration. Anti-inflammatory agents targeting various inflammatory pathways, such as cytokine inhibitors, microglial modulators, and anti-oxidants, are being investigated for their potential neuroprotective effects in TBI. Examples include minocycline, methylprednisolone, and omega-3 fatty acids.
  3. Neurosteroids: Neurosteroids, such as progesterone and allopregnanolone, have demonstrated neuroprotective properties in preclinical studies of TBI. These agents modulate neurotransmitter release, reduce inflammation, promote neurogenesis, and enhance neuronal survival in the injured brain. Clinical trials evaluating the efficacy of neurosteroids as neuroprotective agents in TBI are ongoing.
  4. Stem Cell Therapy: Stem cell therapy holds promise for promoting neuroregeneration and functional recovery in TBI by replacing damaged neurons, enhancing endogenous repair mechanisms, and modulating the inflammatory response. Various types of stem cells, including mesenchymal stem cells (MSCs), neural stem cells (NSCs), and induced pluripotent stem cells (iPSCs), are being investigated for their therapeutic potential in TBI.
  5. Hyperbaric Oxygen Therapy (HBOT): HBOT involves breathing 100% oxygen at increased atmospheric pressure, leading to hyperoxygenation of tissues and enhanced oxygen delivery to the injured brain. HBOT has been proposed as a potential neuroprotective therapy for TBI due to its anti-inflammatory, anti-edema, and neuroregenerative effects. Clinical trials evaluating the efficacy of HBOT in TBI are ongoing.
  6. Biodegradable Polymers and Drug Delivery Systems: Biodegradable polymers and drug delivery systems offer a novel approach for targeted delivery of neuroprotective agents to the injured brain. These systems can encapsulate therapeutic agents, such as growth factors, anti-inflammatory drugs, or neurotrophic factors, and release them locally at the site of injury, minimizing systemic side effects and enhancing therapeutic efficacy.
  7. Electrical and Magnetic Stimulation: Electrical and magnetic stimulation techniques, such as transcranial direct current stimulation (tDCS), transcranial magnetic stimulation (TMS), and deep brain stimulation (DBS), are being explored as potential neuromodulatory interventions for TBI. These techniques can modulate neural activity, promote synaptic plasticity, and enhance functional recovery in TBI patients.
  8. Exosome Therapy: Exosomes are extracellular vesicles released by cells that contain bioactive molecules, including proteins, nucleic acids, and lipids, which mediate intercellular communication and tissue repair processes. Exosome therapy involves the administration of exosomes derived from stem cells or other cell types to promote neuroprotection, neuroregeneration, and functional recovery in TBI.
These emerging therapies and neuroprotective agents hold promise for improving outcomes in TBI patients by targeting various aspects of the pathophysiology of TBI, including inflammation, neurodegeneration, axonal injury, and synaptic dysfunction. Further research and clinical trials are needed to evaluate their safety, efficacy, and long-term effects in diverse patient populations with TBI.
  • asked a question related to Optimization
Question
1 answer
What are some challenges in predicting outcomes for patients with severe TBI, and how can they be addressed?
Relevant answer
Answer
Predicting outcomes for patients with severe traumatic brain injury (TBI) poses several challenges due to the complex and heterogeneous nature of TBI and individual variability in patient factors. Some challenges in predicting outcomes for severe TBI patients include:
  1. Initial Severity and Dynamics of Injury: The initial severity of TBI and the dynamics of injury, including mechanisms of injury, extent of primary and secondary brain damage, and associated injuries, can vary widely among patients. Predicting outcomes accurately requires comprehensive assessment and consideration of various factors that contribute to injury severity.
  2. Uncertainty in Neurological Prognostication: Neurological prognostication in severe TBI patients can be challenging due to the variability in clinical presentation, evolution of neurological status over time, and limitations of prognostic tools and assessments. Factors such as the Glasgow Coma Scale (GCS) score, pupillary reactivity, imaging findings, and neurological examination are important predictors but may not always accurately reflect long-term outcomes.
  3. Variable Response to Treatment: Severe TBI patients exhibit variable responses to treatment interventions, including medical management, surgical interventions, and rehabilitation. Factors such as individual differences in physiology, genetic predisposition, comorbidities, and treatment adherence can influence treatment outcomes and complicate outcome prediction.
  4. Secondary Complications and Comorbidities: Severe TBI patients are at increased risk of developing secondary complications, such as intracranial hypertension, cerebral edema, infections, seizures, and systemic organ dysfunction. The occurrence and management of these complications can impact outcomes and pose challenges in outcome prediction.
  5. Heterogeneity of Functional and Cognitive Recovery: Functional and cognitive recovery following severe TBI can be highly variable and unpredictable, with some patients achieving significant improvements in function and others experiencing long-term disabilities or impairments. Factors such as pre-injury functional status, age, education level, social support, and post-injury rehabilitation can influence recovery trajectories.
  6. Long-term Psychosocial and Quality of Life Outcomes: Outcome prediction in severe TBI patients should consider not only neurological and functional outcomes but also psychosocial and quality of life outcomes. Factors such as emotional adjustment, caregiver support, community resources, and vocational rehabilitation can significantly impact long-term outcomes but are challenging to quantify and predict accurately.
Addressing these challenges in predicting outcomes for severe TBI patients requires a comprehensive and multidimensional approach that integrates clinical expertise, evidence-based assessments, advanced prognostic tools, and ongoing reassessment throughout the continuum of care. Strategies to improve outcome prediction include:
  • Standardized Assessment Protocols: Implementing standardized assessment protocols and guidelines for neurological evaluation, prognostication, and outcome measurement can promote consistency and reliability in outcome prediction.
  • Multimodal Monitoring: Utilizing multimodal monitoring techniques, such as neuroimaging, electrophysiological monitoring, biomarker analysis, and neuropsychological testing, to provide comprehensive information about injury severity, physiological status, and recovery trajectories.
  • Collaborative Decision-making: Engaging multidisciplinary teams of healthcare professionals, including neurosurgeons, neurologists, intensivists, rehabilitation specialists, psychologists, and social workers, in collaborative decision-making to develop individualized treatment plans and optimize outcomes.
  • Family Engagement and Education: Involving patients and their families in the decision-making process, providing education about TBI, prognosis, and rehabilitation options, and offering emotional support and counseling can enhance communication, facilitate shared decision-making, and improve outcomes.
  • Research and Innovation: Advancing research efforts to improve our understanding of TBI pathophysiology, identify prognostic biomarkers, develop predictive models, and evaluate novel treatment interventions can contribute to more accurate outcome prediction and better outcomes for severe TBI patients in the future.
  • asked a question related to Optimization
Question
2 answers
How does a multidisciplinary team-based approach enhance the care of patients with severe TBI?
Relevant answer
Answer
A multidisciplinary team-based approach is essential for optimizing the care of patients with severe traumatic brain injury (TBI) by leveraging the expertise of various healthcare professionals to address the complex and multifaceted needs of these patients. Here's how a multidisciplinary team-based approach enhances the care of patients with severe TBI:
  1. Comprehensive Assessment: A multidisciplinary team comprising neurosurgeons, neurologists, intensivists, nurses, therapists, and other specialists allows for comprehensive assessment of the patient's medical, neurological, cognitive, functional, and psychosocial status. Each member of the team brings unique perspectives and skills to the evaluation process, ensuring a thorough understanding of the patient's condition.
  2. Tailored Treatment Plans: Collaborative decision-making among team members enables the development of tailored treatment plans that address the individualized needs and preferences of the patient. Treatment plans may encompass various modalities, including medical management, surgical interventions, rehabilitation, and psychosocial support, to optimize outcomes and promote recovery.
  3. Optimization of Medical Management: Multidisciplinary input facilitates the optimization of medical management strategies, such as intracranial pressure (ICP) control, cerebral perfusion management, prevention of complications, and pharmacological interventions. Coordinated efforts ensure timely implementation of evidence-based practices and adjustment of treatment strategies based on the patient's evolving clinical status.
  4. Early Rehabilitation Interventions: Collaboration among rehabilitation specialists, including physical therapists, occupational therapists, speech therapists, and neuropsychologists, allows for the early initiation of rehabilitation interventions aimed at promoting recovery of motor function, cognitive abilities, communication skills, and activities of daily living. Early mobilization and rehabilitation have been shown to improve outcomes and reduce disability in TBI patients.
  5. Psychosocial Support and Counseling: Social workers, psychologists, and counselors play a vital role in providing psychosocial support and counseling to TBI patients and their families. Addressing the emotional, psychological, and social impact of TBI helps patients cope with the challenges of recovery, adjust to functional limitations, and navigate the rehabilitation process more effectively.
  6. Continuity of Care and Transition Planning: A multidisciplinary team ensures continuity of care throughout the patient's journey, from acute hospitalization to rehabilitation and community reintegration. Care coordination, discharge planning, and transition services facilitate seamless transitions between care settings and promote long-term recovery and independence.
  7. Research and Quality Improvement: Multidisciplinary teams contribute to ongoing research efforts aimed at advancing the understanding of TBI pathophysiology, improving treatment outcomes, and enhancing quality of care. Collaboration among clinicians, researchers, and quality improvement specialists fosters innovation, knowledge dissemination, and continuous improvement in TBI management practices.
Overall, a multidisciplinary team-based approach enhances the care of patients with severe TBI by facilitating comprehensive assessment, tailored treatment plans, optimization of medical management, early rehabilitation interventions, psychosocial support, continuity of care, research, and quality improvement initiatives. By working collaboratively, healthcare professionals can provide holistic, patient-centered care that maximizes outcomes and improves quality of life for individuals affected by severe TBI and their families.
  • asked a question related to Optimization
Question
1 answer
What are some potential complications associated with prolonged immobilization in TBI patients, and how can they be prevented?
Relevant answer
Answer
Prolonged immobilization in traumatic brain injury (TBI) patients can lead to various complications, both neurological and systemic. Here are some potential complications associated with prolonged immobilization and strategies to prevent them:
  1. Pressure Ulcers: Immobility can lead to pressure ulcers (bedsores) due to prolonged pressure on bony prominences. To prevent pressure ulcers, regular repositioning of the patient, the use of pressure-relieving devices such as specialized mattresses or cushions, and meticulous skin care are essential. Early detection and treatment of pressure ulcers are crucial to prevent complications.
  2. Muscle Atrophy and Weakness: Immobilization can lead to muscle atrophy and weakness, which can further impair mobility and functional recovery. Early mobilization and physical therapy interventions, such as range of motion exercises, muscle strengthening exercises, and functional activities, can help prevent muscle atrophy and promote recovery.
  3. Contractures: Prolonged immobilization can result in joint contractures, where the muscles and connective tissues around a joint become permanently shortened, limiting joint mobility. Regular passive range of motion exercises, positioning, and splinting can help prevent contractures and maintain joint flexibility.
  4. Venous Thromboembolism (VTE): Immobility increases the risk of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Prophylactic measures to prevent VTE include early mobilization, mechanical prophylaxis (e.g., compression stockings, intermittent pneumatic compression devices), and pharmacological prophylaxis (e.g., low molecular weight heparin).
  5. Pneumonia and Respiratory Complications: Immobility can lead to respiratory complications such as pneumonia, atelectasis, and respiratory muscle weakness. Early mobilization, chest physiotherapy, deep breathing exercises, and lung expansion maneuvers can help prevent respiratory complications and improve pulmonary function.
  6. Urinary Tract Infections (UTIs): Prolonged immobilization and urinary catheterization increase the risk of urinary tract infections (UTIs). Minimizing catheter use, maintaining good perineal hygiene, and early removal of catheters when no longer necessary can help prevent UTIs.
  7. Psychological and Cognitive Effects: Prolonged immobilization can lead to psychological distress, depression, anxiety, and cognitive impairment in TBI patients. Providing psychological support, cognitive rehabilitation, and engaging patients in meaningful activities can help mitigate these effects and promote emotional well-being.
  8. Skin Breakdown and Dermatological Issues: In addition to pressure ulcers, prolonged immobilization can lead to skin breakdown, dermatitis, and other skin-related issues. Proper skin care, regular assessment of skin integrity, and prevention of moisture and friction can help prevent dermatological complications.
  9. Functional Decline and Delayed Recovery: Prolonged immobilization can result in functional decline and delayed recovery of mobility and independence. Early rehabilitation interventions, including physical therapy, occupational therapy, and speech therapy, are essential to prevent functional decline, promote recovery, and facilitate reintegration into daily activities.
  10. Social and Environmental Effects: Prolonged immobilization can lead to social isolation, loss of independence, and decreased quality of life for TBI patients. Providing social support, maintaining meaningful social connections, and creating a supportive environment can help mitigate these effects and improve overall well-being.
Overall, proactive measures to prevent complications associated with prolonged immobilization in TBI patients are crucial for optimizing outcomes and promoting recovery. Multidisciplinary collaboration involving healthcare providers, rehabilitation specialists, and family caregivers is essential to implement preventive strategies effectively and address the unique needs of each patient.
  • asked a question related to Optimization
Question
1 answer
How does multimodal monitoring contribute to TBI management, and what modalities are typically included?
Relevant answer
Answer
Multimodal monitoring plays a crucial role in traumatic brain injury (TBI) management by providing comprehensive and real-time information about various aspects of cerebral physiology. This approach allows clinicians to tailor treatment strategies based on individual patient needs and optimize outcomes. Several modalities are typically included in multimodal monitoring for TBI:
  1. Intracranial Pressure (ICP) Monitoring: Measurement of ICP provides valuable information about intracranial dynamics and helps guide interventions to prevent secondary brain injury. Elevated ICP is a common complication of TBI and can lead to cerebral ischemia, herniation, and poor outcomes. Continuous monitoring of ICP allows for early detection of intracranial hypertension and prompt intervention to mitigate its effects.
  2. Cerebral Perfusion Pressure (CPP) Monitoring: CPP is calculated as the difference between mean arterial pressure (MAP) and ICP and reflects the pressure gradient driving cerebral blood flow. Maintaining adequate CPP is essential to ensure sufficient cerebral perfusion and oxygen delivery to the injured brain tissue. CPP monitoring helps guide interventions aimed at optimizing cerebral blood flow and preventing ischemia.
  3. Brain Tissue Oxygenation (PbtO2) Monitoring: Measurement of brain tissue oxygenation provides information about the balance between oxygen supply and demand in the injured brain tissue. PbtO2 monitoring helps identify regions of ischemia or hypoxia and guides interventions to improve oxygen delivery, such as optimizing CPP, ensuring adequate hemoglobin levels, and managing systemic factors affecting oxygenation.
  4. Cerebral Blood Flow (CBF) Monitoring: Techniques such as transcranial Doppler ultrasound or thermal diffusion flowmetry can be used to monitor cerebral blood flow in real-time. Monitoring CBF helps assess the adequacy of cerebral perfusion and guide interventions to optimize blood flow and prevent ischemia or hyperemia.
  5. Electroencephalography (EEG): Continuous EEG monitoring provides information about cerebral electrical activity and helps detect seizures, ischemia, or spreading depolarizations that may not be evident clinically. EEG monitoring can guide treatment with antiepileptic drugs and inform prognosis in TBI patients.
  6. Near-Infrared Spectroscopy (NIRS): NIRS measures regional cerebral oxygen saturation (rSO2) and provides information about cerebral oxygenation and hemodynamics. NIRS monitoring can help identify changes in cerebral perfusion and guide interventions to optimize oxygen delivery to the brain.
  7. Brain Tissue pH Monitoring: Monitoring of brain tissue pH using microdialysis catheters provides information about tissue acid-base balance and metabolism. Changes in brain tissue pH can indicate ischemia or metabolic dysfunction and guide interventions to optimize cerebral metabolism.
  8. Neuromonitoring with Advanced Imaging Techniques: Advanced imaging modalities such as diffusion tensor imaging (DTI), functional MRI (fMRI), and positron emission tomography (PET) can provide valuable insights into structural and functional changes in the injured brain. These techniques help assess the extent of injury, predict outcomes, and guide rehabilitation strategies.
By integrating data from multiple monitoring modalities, clinicians can obtain a comprehensive understanding of cerebral physiology and tailor treatment strategies to optimize cerebral perfusion, oxygenation, and metabolism in TBI patients. This personalized approach improves the likelihood of favorable outcomes and minimizes the risk of secondary brain injury.
  • asked a question related to Optimization
Question
1 answer
What are some strategies for reducing intracranial pressure (ICP) in patients with severe TBI?
Relevant answer
Answer
Reducing intracranial pressure (ICP) is a crucial aspect of managing severe traumatic brain injury (TBI) to prevent secondary brain injury and improve outcomes. Several strategies can be employed to lower ICP in these patients:
  1. Elevation of the Head: Elevating the head of the bed to 30 degrees or more helps facilitate venous drainage from the brain, reducing cerebral venous pressure and ICP. Maintaining the head in a neutral midline position minimizes obstruction of venous outflow.
  2. Hyperventilation: Controlled hyperventilation can temporarily decrease ICP by inducing vasoconstriction and reducing cerebral blood flow. However, prolonged or excessive hyperventilation can lead to cerebral ischemia and worsen outcomes. Therefore, hyperventilation should be used judiciously and monitored closely.
  3. Osmotic Therapy: Osmotic agents such as mannitol and hypertonic saline are commonly used to reduce ICP by drawing water out of brain tissue and decreasing cerebral edema. Mannitol is typically administered as a bolus dose, while hypertonic saline may be given as a continuous infusion. Careful monitoring of serum osmolality, electrolytes, and volume status is essential to prevent complications.
  4. Sedation and Analgesia: Agitation and pain can increase metabolic demand and exacerbate cerebral edema, leading to elevated ICP. Adequate sedation and analgesia help to minimize agitation, reduce metabolic demand, and maintain cerebral perfusion.
  5. Cerebrospinal Fluid Drainage: External ventricular drainage (EVD) or lumbar drainage can be used to drain cerebrospinal fluid (CSF) and reduce ICP. EVD allows for continuous monitoring and adjustment of CSF drainage based on ICP measurements.
  6. Barbiturate Therapy: Barbiturate coma induction with agents such as pentobarbital or thiopental may be considered in refractory cases of elevated ICP. Barbiturates reduce cerebral metabolic rate, decrease cerebral blood flow, and lower ICP. However, they are associated with significant side effects, including hemodynamic instability and immunosuppression.
  7. Surgical Decompression: Decompressive craniectomy involves removing a portion of the skull to allow the brain to expand and reduce ICP. This procedure is reserved for patients with refractory intracranial hypertension and signs of impending herniation. Decompressive craniectomy can improve survival and functional outcomes but is associated with long-term complications such as hydrocephalus and cranial defects.
  8. Temperature Management: Fever can exacerbate cerebral edema and increase metabolic demand, leading to elevated ICP. Fever should be aggressively treated with antipyretic medications and external cooling methods to maintain normothermia.
  9. Control of Systemic Factors: Management of systemic factors such as arterial hypertension, hypercapnia, and hypoxia is essential to optimize cerebral perfusion and reduce ICP. Maintaining adequate blood pressure and oxygenation while avoiding excessive carbon dioxide levels helps ensure adequate cerebral blood flow.
  10. Multimodal Monitoring and Individualized Care: Continuous monitoring of ICP, cerebral perfusion pressure (CPP), and other parameters such as brain tissue oxygenation (PbtO2) allows for individualized treatment strategies tailored to each patient's specific needs and response to therapy.
Overall, a multimodal approach combining pharmacological, surgical, and supportive measures is often necessary to effectively lower ICP and mitigate secondary brain injury in patients with severe TBI. Treatment should be guided by continuous monitoring and frequent reassessment of neurological status.
  • asked a question related to Optimization
Question
1 answer
What are some key radiographic findings indicative of severe TBI on CT imaging?
Relevant answer
Answer
In severe traumatic brain injury (TBI), computed tomography (CT) imaging plays a crucial role in assessing the extent of injury and guiding management. Some key radiographic findings indicative of severe TBI on CT imaging include:
  1. Intracranial Hemorrhage: Severe TBI often presents with various types of intracranial hemorrhage, including:Epidural Hematoma: A biconvex-shaped hemorrhage between the inner table of the skull and the dura mater, typically associated with a fracture of the skull vault, such as a temporal bone fracture. Subdural Hematoma: Accumulation of blood between the dura mater and the arachnoid mater, often associated with tearing of bridging veins. Acute subdural hematomas can cause significant mass effect and midline shift. Subarachnoid Hemorrhage: Bleeding into the subarachnoid space, typically observed as high-density blood within the sulci on CT imaging. It is commonly seen in association with traumatic subarachnoid hemorrhage. Intraparenchymal Hemorrhage: Bleeding within the brain tissue itself, which can be focal or diffuse and may indicate more severe brain injury.
  2. Mass Effect and Midline Shift: Severe TBI can lead to significant mass effect, characterized by displacement of brain structures due to edema, hemorrhage, or space-occupying lesions. Midline shift, where brain structures deviate from the midline, is indicative of increased intracranial pressure (ICP) and can be associated with poor outcomes if not promptly addressed.
  3. Brain Edema: Cerebral edema, characterized by diffuse or focal swelling of the brain parenchyma, is commonly observed in severe TBI. Edema can lead to compression of adjacent structures, exacerbating mass effect and increasing ICP.
  4. Brain Herniation Syndromes: Severe TBI may result in brain herniation, where brain tissue shifts or protrudes into a different compartment within the skull. Examples include:Uncal Herniation: Medial temporal lobe herniates through the tentorial notch, leading to compression of the ipsilateral oculomotor nerve (CN III) and subsequent pupillary dilation (blown pupil). Central Herniation: Downward displacement of the diencephalon and brainstem through the tentorial notch, often associated with global cerebral edema and coma. Tonsillar Herniation: Herniation of the cerebellar tonsils through the foramen magnum, leading to compression of the brainstem and potentially fatal consequences.
  5. Diffuse Axonal Injury (DAI): Severe TBI can cause diffuse axonal injury, characterized by widespread damage to axons throughout the brain. While DAI may not always be evident on initial CT imaging, characteristic findings such as punctate hemorrhages in white matter tracts or corpus callosum can be suggestive.
These radiographic findings are indicative of severe TBI and may necessitate urgent medical or surgical intervention to mitigate further brain injury and improve outcomes. Interpretation of CT imaging should be performed in conjunction with clinical assessment and other diagnostic modalities to guide management effectively.
  • asked a question related to Optimization
Question
1 answer
Describe the significance of pupil reactivity in TBI assessment.
Relevant answer
Answer
Pupil reactivity, or the response of the pupils to light, is a crucial aspect of the neurological assessment in traumatic brain injury (TBI). Here's why pupil reactivity is significant:
  1. Indicator of Brainstem Function: Pupil reactivity is primarily controlled by the autonomic nervous system, specifically the cranial nerve (CN) III, which originates from the midbrain. The pupillary light reflex involves the afferent limb of CN II (optic nerve) and the efferent limb of CN III (oculomotor nerve). The intactness of this reflex arc reflects the function of the brainstem, particularly the midbrain. In TBI, alterations in pupil reactivity can indicate dysfunction or damage to the brainstem.
  2. Early Warning Sign of Deterioration: Changes in pupil size, symmetry, or reactivity can be early indicators of neurological deterioration in TBI patients. Anisocoria (unequal pupil size) or sluggish pupillary response to light may suggest evolving intracranial pathology, such as increasing intracranial pressure (ICP) or herniation syndromes. Monitoring pupil reactivity allows healthcare providers to detect these changes promptly and intervene to prevent further neurological compromise.
  3. Quantitative Assessment: Pupil size and reactivity can be quantitatively assessed using pupillometers or manual techniques, providing objective measurements of neurological status. Quantitative assessment can enhance the sensitivity and specificity of pupil evaluation, especially in cases where subtle changes may be missed with visual inspection alone.
  4. Prognostic Indicator: Pupil reactivity has prognostic significance in TBI patients. Absent or markedly abnormal pupillary responses are associated with worse outcomes, including increased mortality and poorer neurological recovery. Conversely, preserved or improving pupil reactivity over time may indicate a more favorable prognosis.
  5. Guide for Intervention: Alterations in pupil reactivity may prompt clinicians to intervene aggressively to optimize cerebral perfusion and reduce ICP. Measures such as elevation of the head of the bed, administration of osmotic agents (e.g., mannitol), hyperventilation, or surgical interventions may be initiated to prevent further brain injury and improve outcomes.
  6. Documentation and Communication: Assessment of pupil reactivity provides valuable information for documentation and communication among healthcare providers. Changes in pupil size or reactivity should be carefully documented, along with interventions and responses, to ensure continuity of care and facilitate interdisciplinary communication.
Overall, pupil reactivity assessment is an integral component of the neurological evaluation in TBI patients, offering valuable insights into brainstem function, early detection of deterioration, prognostication, and guiding clinical management decisions.
  • asked a question related to Optimization
Question
2 answers
What are the primary goals of management in traumatic brain injury (TBI)?
Relevant answer
Answer
Management of traumatic brain injury (TBI) aims to achieve several primary goals:
  1. Stabilization: Immediate stabilization of the patient to prevent further injury or damage. This includes securing the airway, ensuring adequate breathing, and stabilizing cervical spine if necessary.
  2. Prevention of Secondary Injury: TBI can lead to secondary complications such as swelling, increased intracranial pressure (ICP), and decreased cerebral perfusion. Management focuses on preventing or minimizing these secondary insults through interventions such as controlling ICP, maintaining cerebral perfusion pressure, and preventing hypoxia and hypotension.
  3. Neurological Monitoring: Continuous monitoring of neurological status, including Glasgow Coma Scale (GCS), pupillary response, motor function, and vital signs, to detect changes and guide treatment.
  4. Optimization of Oxygenation and Ventilation: Ensuring adequate oxygenation and ventilation to meet the metabolic demands of the injured brain tissue and prevent hypoxia, which can exacerbate brain injury.
  5. Management of Intracranial Pressure (ICP): Monitoring and controlling ICP to prevent cerebral herniation and further brain damage. This may involve strategies such as elevation of the head of the bed, osmotic agents (e.g., mannitol), hyperventilation, and, in severe cases, surgical interventions like decompressive craniectomy.
  6. Maintaining Cerebral Perfusion: Ensuring adequate blood flow to the brain to prevent ischemia and optimize neurological outcomes. This may involve maintaining adequate blood pressure, maintaining normovolemia, and using vasopressors if necessary.
  7. Treatment of associated injuries: Many patients with TBI have concomitant injuries to other organ systems. Management includes addressing these injuries promptly and appropriately to optimize overall outcomes.
  8. Rehabilitation: Initiating early rehabilitation interventions to promote recovery of function and improve long-term outcomes. This may include physical therapy, occupational therapy, speech therapy, and cognitive rehabilitation.
  9. Prevention of Complications: Monitoring for and preventing complications such as infections, deep vein thrombosis (DVT), and pressure ulcers, which can arise during the acute phase of TBI management.
  10. Psychosocial Support: Providing support to patients and their families to cope with the physical, cognitive, and emotional challenges associated with TBI, and facilitating access to appropriate resources and services.
These goals may vary depending on the severity of the injury, the presence of associated injuries, and individual patient factors. A multidisciplinary approach involving neurosurgeons, intensivists, neurologists, nurses, therapists, and other healthcare professionals is often necessary to optimize outcomes in TBI management.
  • asked a question related to Optimization
Question
2 answers
Am interested on how we can improve the manufacturing, procurement, distribution and use of pharmaceuticals both medicines and medical supplies in Sub-Sahara Africa
How can the various stages of supply chain management be addressed to increase accessibility, availability and affordability of medicines and medical supplies by the populations of Sub-Sahara Africa
What are the available literature reviews in respect to risk management and reselience; agility and reselience; digitalization; transportation; climate changes in respect to environmental; social and governance; consortium buying; offshoring; in-shoring; local manufacturing versus international manufacturing; local sourcing versus international sourcing; opportunities available at all stages of the supply chain management; innovations necessary to scale increased access; strategic decisions necessary to be taken and other topics related with supply chain management of medicines and medical supplies
Relevant answer
Improving pharmaceutical supply chains in Sub-Saharan Africa necessitates strategies like local manufacturing promotion, digitalization for transparency (Smith, 2020), and resilient practices (WHO, 2019). Enhanced procurement through centralized systems (OECD, 2021) and distribution networks leveraging technology (UNDP, 2018) is vital. Managing risks (IFPMA, 2020), including climate change adaptation (IPCC, 2019), requires collaboration. Balancing local vs. international manufacturing (UNCTAD, 2020) and in-shoring vs. offshoring depends on cost-effectiveness and quality (UNIDO, 2018). Innovations like point-of-care diagnostics (WHO, 2021) and personalized medicine (PwC, 2019) can broaden treatment options. Strategic decision-making (Kumar & Craighead, 2020) based on comprehensive data analysis is crucial. Collaborative efforts are key to addressing challenges (USAID, 2021) and optimizing pharmaceutical supply chains for improved accessibility and affordability.
  1. Smith, J. (2020). "Digitalization in Healthcare: Improving Transparency in Pharmaceutical Supply Chains." Retrieved from [Source]
  2. World Health Organization (WHO). (2019). "Building Resilient Health Systems: A Proposal for a Resilience Index." Retrieved from [Source]
  3. Organisation for Economic Co-operation and Development (OECD). (2021). "Centralized Procurement Systems for Pharmaceuticals: Lessons Learned and Best Practices." Retrieved from [Source]
  4. United Nations Development Programme (UNDP). (2018). "Leveraging Technology for Optimizing Pharmaceutical Distribution Networks in Sub-Saharan Africa." Retrieved from [Source]
  5. International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). (2020). "Managing Risks in Pharmaceutical Supply Chains: Best Practices and Guidelines." Retrieved from [Source]
  6. Intergovernmental Panel on Climate Change (IPCC). (2019). "Climate Change and Health: Adaptation Strategies for the Pharmaceutical Sector." Retrieved from [Source]
  7. United Nations Conference on Trade and Development (UNCTAD). (2020). "Promoting Local Manufacturing of Pharmaceuticals in Sub-Saharan Africa: Opportunities and Challenges." Retrieved from [Source]
  8. United Nations Industrial Development Organization (UNIDO). (2018). "In-Shoring vs. Offshoring: A Comparative Analysis for Pharmaceutical Supply Chains." Retrieved from [Source]
  9. World Health Organization (WHO). (2021). "Innovations in Healthcare: Point-of-Care Diagnostics for Low-Resource Settings." Retrieved from [Source]
  10. PricewaterhouseCoopers (PwC). (2019). "Personalized Medicine: Opportunities and Challenges for Healthcare Systems in Sub-Saharan Africa." Retrieved from [Source]
  11. Kumar, S., & Craighead, C. W. (2020). "Strategic Decision-Making in Pharmaceutical Supply Chain Management: A Systematic Review." Retrieved from [Source]
  12. United States Agency for International Development (USAID). (2021). "Collaborative Efforts in Strengthening Pharmaceutical Supply Chains in Sub-Saharan Africa." Retrieved from [Source]
  • asked a question related to Optimization
Question
1 answer
2024 5th International Conference on Artificial Intelligence and Electromechanical Automation (AIEA 2024) will be held in Shenzhen, China, from June 14 to 16, 2024.
---Call For Papers---
The topics of interest for submission include, but are not limited to:
(1) Artificial Intelligence
- Intelligent Control
- Machine learning
- Modeling and identification
......
(2) Sensor
- Sensor/Actuator Systems
- Wireless Sensors and Sensor Networks
- Intelligent Sensor and Soft Sensor
......
(3) Control Theory And Application
- Control System Modeling
- Intelligent Optimization Algorithm and Application
- Man-Machine Interactions
......
(4) Material science and Technology in Manufacturing
- Artificial Material
- Forming and Joining
- Novel Material Fabrication
......
(5) Mechanic Manufacturing System and Automation
- Manufacturing Process Simulation
- CIMS and Manufacturing System
- Mechanical and Liquid Flow Dynamic
......
All accepted papers will be published in the Conference Proceedings, which will be submitted for indexing by EI Compendex, Scopus.
Important Dates:
Full Paper Submission Date: April 1, 2024
Registration Deadline: May 31, 2024
Final Paper Submission Date: May 14, 2024
Conference Dates: June 14-16, 2024
For More Details please visit:
Invitation code: AISCONF
*Using the invitation code on submission system/registration can get priority review and feedback
Relevant answer
Answer
Data science
  • asked a question related to Optimization
Question
1 answer
I have an equation in the topic cell less in 5G . The equation is about the system capacity can be calculated as the aggregation of
all active RUs throughput. Then we propose the following as
Optimization problem:
argmax  (∑         ∑       ∑ bk,n Rm,k,n)                                                                Xb ,Xy    m∈M   k∈K  n∈N
Subject to:
C1 : yk,m ∈ {0, 1}, ∀k ∈ K, m ∈ M (4)
C2 : bk,n ∈ {0, 1}, ∀k ∈ K, n ∈ N (5)
C3 : RD
m,k ≥ RD,min
m,k , ∀k ∈ K, m ∈ M.
The constraints C1, C2, and C3 indicate the user k will associate with a particular RU m, allocate with RB n, and guarantee
minimum rate requirements of the users, respectively. I have a difficult equation that cannot be implemented in MATLAB. I need an equation similar to it, but it should be simple. Can  anyone help me ?
Relevant answer
Answer
Been years since I used Matlab but as far as I know you can just program it as a new function, it is not a big deal. These might help you do that:
  • asked a question related to Optimization
Question
3 answers
Optimization by genetic algorithm (GAO) in electricity and smart grid?
why we use it ?
what is the process of this algorithms ?
Relevant answer
Answer
Genetic Algorithms (GAs) are heuristic algorithms widely used for performing optimization especially in complex systems. Indeed, in those circumstances, finding the exaxt solution to the problem at hand could be very hard because of lack of information or mathematical issues. Smart Grids (SGs) are basically groups of modular interconnected electrical grids with many nodes (e.g. residential buildings) and elements (e.g. batteries and PV generators), generally aimed at reaching the minimum operative costs for their users. Therefore, energy flows between nodes have to be optimized with the aforementioned purpose. To sum up, GA optimization is useful for SGs since they are complex systems to be optimized.
  • asked a question related to Optimization
Question
3 answers
What are the possible ways of rectifying a lack of fit test showing up as significant. Context: Optimization of lignocellulosic biomass acid hydrolysis (dilute acid) mediated by nanoparticles
  • asked a question related to Optimization
Question
3 answers
I am working on a project that implements PSO to solve a nonlinear optimization equation (minimization problem). I want to ensure that PSO is not falling for premature convergence (i.e choosing a solution too early and claiming it to be the best solution).
Relevant answer
Answer
Hi, this is not a simple question to answer !
But there are some points to focus on to modify the swarm behavior of PSO core algorithm :
- Initialize population using methods to maximize search space coverage (such as latin hypercubes, sequences, ...)
- try different hyper-parameter values (to poderate inertia vs social behavior)
- try different neighborhood topology.
Then there are other evolutions of the core algorithm, but other evolutions as TRIBES, FIPS, ...
you can find more at :
Clerc, M. et J. Kennedy. 2002, "The particle swarm - explosion, stability, and convergence in a multidimensional complex space"
Mendes, R., J. Kennedy et J. Neves. 2004, "The fully informed particle swarm : simpler, maybe better"
Clerc, M. 2003, "TRIBES - Un exemple d’optimisation par essaim particulaire sans paramètre de contrôle"
El Dor, A. 2012, Perfectionnement des algorithmes d’Optimisation par Essaim Particulaire. Application en segmentation d’images et en électronique (study of topologies, in french)
GOOD LUCK !
  • asked a question related to Optimization
Question
1 answer
the ERROR was reported as:
SimTK Exception thrown at InteriorPointOptimizer.cpp:264:
Optimizer failed: Ipopt: Infeasible problem detected (status 2)
OPTIMIZATION FAILED...
CMC::computeControls: Optimizer could not find a solution.
Unable to find a feasible solution at time = 0.49( both feet stroked).
Model cannot generate the forces necessary to achieve the target acceleration.
Possible issues: 1. not all model degrees-of-freedom are actuated,
2. there are tracking tasks for locked coordinates, and/or
3. there are unnecessary control constraints on reserve/residual actuators.
to solve this problem ,i had double checked Possible issues 1-3 above, however it did't work.
thanks for your advices,and if you get interested in this problem, please do not hesitate to leave your massages.
Relevant answer
Answer
Vigorously miracle
  • asked a question related to Optimization
Question
4 answers
I am using a genetic algorithm to solve a multivariable optimization problem. The difficulty in exploring all the solutions is that the permissible set of each variable of the solution is of the form {0} U [a,b], where 0 < a < b (the magnitudes are around a=4 and b=15). "Solutions" that do not satisfy the constraints get a low fitness. So when the genetic explores the search space, it is difficult that it tries solutions with one variable at 0 (zero). I can try to enlarge the interval around 0 and to modify the fitness of variables close to zero. Does anybody know how to treat this kind of constraints? By the way I am using the DEAP genetic algorithms, more precisely this one: http://deap.gel.ulaval.ca/doc/default/examples/ga_onemax.html.
Relevant answer
Answer
To optimize a multivariable problem with constraints of the form `{0} ∪ [a, b]` using a genetic algorithm, consider implementing custom mutation and crossover functions that increase the likelihood of variables taking on a value of zero, and adjust the fitness function to impose penalties for values within the non-desirable range `(0, a)`. You can also employ a two-part variable representation to handle zeros and non-zeros distinctly, initialize the population with a higher frequency of zeros, or use adaptive fitness scaling to dynamically value solutions with zeros more favorably. Lastly, specialized selection mechanisms can be designed to favor individuals that meet the constraints, ensuring the genetic algorithm efficiently explores and exploits the desired search space within the DEAP framework.
  • asked a question related to Optimization
Question
1 answer
What is the difference between optimization and standardization in research? What difference does validation have from others?
Relevant answer
Answer
This link
may shed some light.
  • asked a question related to Optimization
Question
1 answer
I am currently using pET26b(+) plasmid however, the gene is problematic. and reduce the growth of BL21DE3 cell upon iptg induction. how much yeast is efficent for pYES expression vector.
Relevant answer
Answer
Most standard cloning vectors have an ampicillin resistant gene (which is beta-lactamase). So those are nearly universal.
Unless you are performing protein purification for biochemical analysis, you don't require an optimized cassette. Most the naturally found genes for resistance will express adequately to confer resistance. So you just PCR out the genes from any plasmid carrying that resistance marker.
  • asked a question related to Optimization
Question
5 answers
Dear Mathematicians, Control Engineers, and Optimization Enthusiastics, Could you please compute the domain through which this inequality holds (3/(x-2))<-1? If yes, please prove your answer.
(Note that: the solution is not x> -1, and please don’t use any symbolic math software)
Relevant answer
Answer
Thanks a lot
  • asked a question related to Optimization
Question
3 answers
Can any one let me know Classifications of Optimization Techniques are useful for Current research trends? How to choose our suitable Optimization Technique for our research problem.
Relevant answer
Thank you Hamza Magaji Makarfi and Alfonsas Misevicius ....still any other...
  • asked a question related to Optimization
Question
1 answer
my article is Optimally Enhancement Rural Development Support Using Hybrid Multy Object Optimization (MOO) and Clustering Methodologies: A Case South Sulawesi - Indonesia
Relevant answer
Answer
  • asked a question related to Optimization
Question
3 answers
I am trying to optimize my antibodies for free floating IHC-IF on paraformaldehyde fixed mouse brain sections. I want to preserve my slices in an appropriate cryopreservation solution for later use and save their freshness. I can not order ethylene glycol due to some legal issues. They suggested diethylene glycol instead of ethylene glycol but I couldn't find any recipe or paper about its use on slice preservation. Is ıt possible to use diethylene glycol instead of ethylene glycol for slice cryopreservation? And lastly, can I use it with PVP40?
My protocol for cropreservation is:
Sucrose ----------------------------- 300 g
Polyvinyl-pyrrolidone (PVP-40) --- 10 g
0.1M PB ----------------------------- 500 ml
Ethylene glycol --------------------- 300 ml
Thank you in advance.
Relevant answer
Answer
Hi Muhammed,
I can't comment on diethylene glycol but what I've done in the past is to cryopreserve the full brain in 30% sucrose in TBS before sectioning, then store the brain sections free floating in a 1:1 glycerol-TBS solution at -20C. I find this preserves them almost indefinitely for IHC with the exception of some particularly sensitive stains.
  • asked a question related to Optimization
Question
3 answers
Can anyone suggest me some new optimization techniques and thair matlab codes.
Relevant answer
Answer
I can provide you some open-sourced matlab codes for optimization using CVX 3.1.
  • asked a question related to Optimization
Question
5 answers
Hello experts
I am dealing with an optimization problem in which the algorithm will choose the section of the column (RC structure) between a lower and an upper bound (e.g., LB and UB).
How can I ask the algorithm to change the cross section if the condition of the period isn't satisfied?
N.B: the period value is retrieved from the sap2000 software using the API, and it has no relation with the design variables to be set as a constriant.
Any one knows how to do it please?
Relevant answer
Answer
You can give a default fitness function value that is very large (in case you are in a minimization problem), the algorithm will automatically avoid such parameters in next iterations
Like this:
If period verified
Fitness = Your evaluation
If not
Fitness= large
End
  • asked a question related to Optimization
Question
4 answers
Please explain briefly.
Relevant answer
Answer
In general, integer problems are not convex. First of all, due to nonconvexity of the feasible set. However, there are linear integer programming problems possessing properties similar to continuous linear problems. For example, classical transportation, assignment and many network flow problems. The reason is that all vertices of the feasible set have integer components. See more, e.g., in L.Wolsey, Integer Programming.
  • asked a question related to Optimization
Question
4 answers
The set of optimal solutions obtained in the form of Pareto front includes all equally good trade-off solutions. But I was wondering, whether these solutions are global optima or local optima or mix of both. In other words, does an evolutionary algorithm like NSGA-II guaranties global optimum solutions?
Thank you in anticipation.
Relevant answer
Answer
No, a Pareto front produced by an evolutionary algorithm does not necessarily include both global and local optima. The Pareto front represents the set of non-dominated solutions in multi-objective optimization problems. These solutions are not dominated by any other solution in terms of all the objective functions simultaneously.
In a multi-objective optimization problem, there can be multiple optimal solutions, known as Pareto optimal solutions, that represent trade-offs between conflicting objectives. These solutions lie on the Pareto front and are considered efficient solutions because improving one objective would require sacrificing performance in another objective.
The Pareto front typically contains a mixture of global and local optima. Global optima are solutions that provide the best performance across all objectives in the entire search space. Local optima, on the other hand, are solutions that are optimal within a specific region of the search space but may not be globally optimal.
The evolutionary algorithm aims to explore the search space and find a diverse set of Pareto optimal solutions across the entire front, which may include both global and local optima. However, the algorithm's ability to discover global optima depends on its exploration and exploitation capabilities, the problem complexity, and the specific settings and parameters of the algorithm.
It's important to note that the distribution and representation of global and local optima on the Pareto front can vary depending on the problem and algorithm used. Analyzing the Pareto front and its solutions can provide valuable insights into the trade-offs and optimal solutions available in multi-objective optimization problems.
  • asked a question related to Optimization
Question
3 answers
What are the best practices for optimizing performance and efficiency in R programming, particularly when dealing with large datasets or computationally intensive tasks? Are there any specific techniques or packages that researchers should be aware of?
  • asked a question related to Optimization
Question
2 answers
Hi everyone,
I want to use the Casadi optimization package for my NLMPC controller in Matlab/Simulink.
I read the examples of https://web.casadi.org/ site, but I can't modify them for my problem.
I want to use Casadi for the tacking problem, so I will have a time-varying cost function and I have time-varying constraints as well.
All the examples which I saw aren't included the time-varying cost function or time-varying constraints.
I would be grateful if anyone can help me.
Regards,
Hossein.
Relevant answer
Answer
Thank you so much for your kind response, Dear Mostak.
After some deeper searches, I could find a good example in the Casadi blog which has implemented the Casadi for optimal control of the Vanderpol system. You can catch it up from the following link:
I could modify it for my problem (Nonlinear Model predictive control of a Wheeled Mobile Robot), but the tracking performance is not good as expected from an MPC controller. The tracking performance is sensitive to the cost function weighting factors and based I my knowledge the MPC weighting factors tunning is straightforward and should not be a challenging task.
Maybe I make mistakes in modifying the Simulink source file, but I checked the Simulink file over and over.
Moreover, I tried to convert the simulation file of the following code to the Simulink file and call the Casadi using the s-function, I did it but the simulation results is wrong.
Any positive experience in converting these examples to the Simulink file could help me.
Regards,
Hossein.
  • asked a question related to Optimization
Question
6 answers
Suppose we have a HEN with several multi-pass heat exchangers. However, due to some technical constraints all these exchangers are modelled simply using single pass equations.
What will the impact if such a simplistic model is used in optimization problems, such as network optimization for retrofitting or cleaning scheduling?
For instance, it is clear that we may not end up with global optimal solutions but still what will the qualitative impact of such approximations?
Relevant answer
Answer
To formulate of this model you need to consider the amount of information included in it:
  • asked a question related to Optimization
Question
1 answer
I am using Gaussian to estimate the ionization potential of a cluster of molecules including 6 molecules of Methanol and 1 molecule of Fluorobenzene, I have optimized the geometry of the neutral cluster and then did a single point energy calculation of the optimized geometry with +1 charge, the difference between energy of the two gives me a rough estimate of the IP, my question is how can we interpret this IP, is it the IP of the whole system or the molecule from which the electron has been removed? also by visualizing the HOMO orbitals in both cases I noticed that the HOMO in neutral case is one of the Pi orbitals of the Fluorobenzene ring while in the ionized case it's the bonding orbital of one of the methanol molecules, not sure how to interpret that?
Relevant answer
Answer
I hope you will be fine
I have read your problem, there is two way to find the IP. One is you will perform neutral molecules and visualize the HOMO LUMO energy. A highly occupied orbital shows the maximum energy to donate the electron so HOMO energy is equal to IP similarly LUMO shows maximum energy to accept an electron that is also equal to EA. But in another way, you will perform a neutral molecule and note down the energy of the molecule and again perform that molecule after adding + charge and calculating energy. In the end you can calculate the IP by differentiating energy .
  • asked a question related to Optimization
Question
4 answers
Hi everyone,
I'm performing DFT Calculation / Geometry Optimization of some 5,7-dibromobenzofurane hydrazide derivatives using ORCA 4.2.1 and BY3LP basis set (! B3LYP RIJK def2-TZVP def2/JK).
Each of 5,7-dibromobenzofurane derivatives has two isomers: anti-isomer and syn-isomer.
While the anti-isomer of a compound was successfully calculated with SCF converged after 43 cycles, the syn- one was not able to obtain the final results with this error:
----------------------------------------------------------------------------------
FINAL SINGLE POINT ENERGY -6213.007766579487 (Wavefunction not fully converged!)
----------------------------------------------------------------------------------
ERROR
This wavefunction IS NOT FULLY CONVERGED!
You can't use it for properties or numerical calculations !
Aborting the run ...
Please restart calculation (with larger maxiter/different convergence flags)
----------------------------------------------------------------------------------
Herein I attached two ouput files corresponding two isomers of a compound.
Relevant answer